Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

ed, "We would like to thank Dr. Richardson, Dr. Anderson and the other clinical investigators involved for their dedication to the perifosine multiple myeloma development program."

Dr. Richardson stated, "Despite recent advances, multiple myeloma remains a devastating and challenging disease for which we believe combination treatment will be beneficial to the majority of patients. We are very encouraged by the perifosine + bortezomib combination in regards to overall response rate, progression-free survival and overall survival data observed to date. If the results from this Phase 3 study prove positive, we believe that this orally administered novel agent could make an important difference for patients with advanced multiple myeloma."

Dr. Ken Anderson commented, "We are very excited to be leading this pivotal program alongside our multiple myeloma colleagues nationwide. Based on the synergies observed in preclinical models, and most importantly, the clinical data generated in the Phase 1/2 study, we believe the combination of perifosine with bortezomib can significantly improve patient outcomes in this disease."

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico. In addition to multiple myeloma, other clinical development efforts with perifosine are focused in the areas of colorectal cancer, renal cell carcinoma and other tumor types.

About the Phase 3 Trial Design

The Phase 3 trial is a randomized (1:1), double-blind trial comparing the efficacy and safety of KRX-0401 (perifosine) to placebo when combined with bortezomib and dexamethasone in approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. Patients will be randomized to bortezomib at 1.3 mg/m2 days 1, 4, 8 and 11 every 21 days in combination with dexamethasone 20 mg on the day of and day after bortezomib treatment, and either perifosine 50 mg daily or placebo
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Research and Markets ... addition of the "Latest Regulations on Pharmaceutical ... to their offering. This is first ... a guidance on international multi-center clinical trials of ... has begun to be implemented on March 1, ...
(Date:5/22/2015)... -- In a sweeping analysis assessing the current state of ... researchers conclude that there remains considerable room for improving ... groups, but especially for adolescents and young adults. The ... underscoring the need to address barriers to care and ... 1 patients achieve optimal metabolic control. ...
(Date:5/22/2015)... REDWOOD CITY, Calif. , May 22, 2015 /PRNewswire/ ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today announced that interim chief executive officer ... 2015 Healthcare Conference and chief financial officer Tim ... Science Conference. Details of the two presentations are as ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... 15, 2011 Irvine Pharmaceutical Services is pleased to ... Irvine,s analytical management team as the new Manager of ... of analytical experience.  Dr.  Al-Ammar has over fourteen years ... papers published in both the United States and Europe. ...
... 2011 ViroPharma Incorporated (Nasdaq: VPHM ... granted ViroPharma Centralized Marketing Authorization for Cinryze® (C1 ... angioedema (HAE) for routine prevention, pre-procedure prevention and ... includes a self administration option for appropriately trained ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 2ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 3ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 4ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 5ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE) 6
(Date:5/23/2015)... On Wednesday, May 20, 2015, CareFirst ... been the target of a sophisticated cyberattack,” and that ... ongoing Information Technology (IT) security efforts in the wake ... most notable attack on health insurers was reported in ... second largest health insurer, revealed that they had suffered ...
(Date:5/23/2015)... Manufacturers are now required to produce water heaters ... Experts in the field agree that the regulation is aimed ... score is what miles per gallon is to your car. ... the minimum HSPF score has been raised to 8.2, technology ... north of 12. Indeed, the regulation was welcomed by environmentalist, ...
(Date:5/23/2015)... May 23, 2015 Javon Bea ... the Sports Medicine and Rehabilitation Center, 557 N. Washington ... Mondays, June 1-July 20, 5:30-6:30 pm. , The 8-week ... and Laurie Finke, RN, BSN, who will offer training ... on nutrition, running mechanics and show selection and weekly ...
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on ... Maryland legislature but which has not been signed to date ... HB 449 with overwhelming bipartisan support on April 10, ... law. This bill ensures that fracking is prohibited in Maryland ... danger of fracking to our water supplies and the air ...
(Date:5/22/2015)... May 22, 2015 Pioneer Millworks, the ... the forefront of designing with reclaimed wood, introducing their ... Los Angeles, California. Their newest offerings, Vat 35, ... surface and color to America's largest design event. , ... at each show, anxious to see and feel the ...
Breaking Medicine News(10 mins):Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3
... adds to growing list of solutions available to help companies ... , DEERFIELD, Ill., June 4 Knowledge and prevention ... you may look or feel healthy, you may not know ... illness. , , That is why Focused Health Solutions, ...
... studies highlight benefits of ACTEMRA as a treatment for ... 4 Roche today announced that oral and poster ... clinical development program will be presented at the 10th ... which will take place June 10-13, 2009, in Copenhagen, ...
... June 4 /PRNewswire-Asia/ -- For the first time in ... to gain business insight,and forge strategic alliances at the ... the medical tourism industry worldwide is,growing at 15-20% annually, ... than US$4.4 billion by 2012. As the region,s premier ...
... natural relief for pain, strengthening of immune systems and more ... and more research is showing that most illness, disease and ... health of the cellular immune system with essential nutrition. Key ... essential nutrients and water. This is something that,s become more ...
... On April 13, 2009, the Trademark Trial and Appeal Board ... LLC,s ("Vision Pharma") motion for judgment on the pleadings and ... to Cornerstone Therapeutics, Inc.,s (Nasdaq: CRTX ) ("Cornerstone") ... Vision Pharma,s pending trademark application for the mark VISRX, Cornerstone ...
... 4 - Cepheid (Nasdaq: CPHD ) today ... HAI Testing: Good Medicine and Good Business," which the ... in Infection Control (APIC) annual conference, taking place in ... Systems and menu of molecular diagnostic tests will be ...
Cached Medicine News:Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 2Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 3Health News:ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress 2Health News:ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress 3Health News:ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress 4Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 2Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 3Health News:Breakthrough Nanotechnology Delivers Safe, Nutrition-Packed Cellular Hydration 2Health News:Breakthrough Nanotechnology Delivers Safe, Nutrition-Packed Cellular Hydration 3Health News:Vision Pharma Is Granted Motion for Judgment 2Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 2Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: